<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26442/2075082X.2019.2.180164</article-id><article-id custom-type="elpub" pub-id-type="custom">systhiper-581</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Лекарственно-индуцированная артериальная гипертония</article-title><trans-title-group xml:lang="en"><trans-title>Drug-induced arterial hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostroumova</surname><given-names>O. D.</given-names></name></name-alternatives><email xlink:type="simple">ostroumova.olga@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куликова</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulikova</surname><given-names>M. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»; ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» - ОСП «Российский геронтологический научно-клинический центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Yevdokimov Moscow State University of Medicine and Dentistry; Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Yevdokimov Moscow State University of Medicine and Dentistry</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>16</volume><issue>2</issue><fpage>32</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Остроумова О.Д., Куликова М.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Остроумова О.Д., Куликова М.И.</copyright-holder><copyright-holder xml:lang="en">Ostroumova O.D., Kulikova M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/581">https://www.syst-hypertension.ru/jour/article/view/581</self-uri><abstract><p>Данный обзор посвящен проблеме лекарственно-индуцированной артериальной гипертонии (АГ). В нем обобщены литературные данные о лекарственных средствах и веществах, которые могут повышать артериальное давление, рассматриваются механизмы их гипертензивного действия. Многие классы лекарственных средств, такие как стероиды, нестероидные противовоспалительные препараты, симпатомиметики, иммунодепрессанты, оральные контрацептивы, антидепрессанты, эритропоэтин и другие, могут вызывать лабильное или стойкое повышение артериального давления, стать причиной неконтролируемой АГ, уменьшать эффективность антигипертензивных препаратов. Развитие лекарственно-индуцированной АГ реализуется посредством ряда патофизиологических механизмов: задержка натрия c последующим увеличением объема циркулирующей крови, активация симпатической нервной системы, прямое воздействие на гладкую мускулатуру артериол, существуют и другие, не до конца изученные механизмы. Лекарственно-индуцированная АГ может также являться результатом фармакокинетического или фармакодинамического взаимодействия лекарственных средств. Подозревать наличие лекарственно-индуцированной АГ, в первую очередь, следует у лиц с впервые диагностированной АГ, а также у пациентов, ранее имевших хорошо контролируемую АГ (стабильные целевые цифры артериального давления - АД) при возникновении у них эпизодов необъяснимого повышения АД без четкой взаимосвязи с физической или психоэмоциональной нагрузкой. Очень важен правильно собранный анамнез с фокусом на тщательную оценку принимаемых пациентом лекарственных средств, особенно вновь назначенных, а также купленных в аптеке самостоятельно, в том числе безрецептурных, это позволит избежать лишних и/или дорогостоящих исследований и ненужных назначений дополнительных антигипертензивных препаратов. В статье приведены меры по профилактике и коррекции лекарственно-индуцированной АГ. Назначение врачом новых лекарственных средств пациентам, получающим антигипертензивную терапию, в обязательном порядке должно учитывать их влияние на риск развития лекарственно-индуцированной АГ. Назначения препаратов, вызывающих повышение АД, следует либо избегать, либо, в том случае, если альтернативные схемы лечения невозможны, обязателен строгий контроль уровня АД у пациента (включая метод домашнего мониторирования АД) и, при необходимости, коррекция проводимой антигипертензивной терапии. При отмене лекарственного средства, вызывающего лекарственно-индуцированную АГ, АД возвращается к исходным значением, что является доказательством ятрогенной причины АГ.</p></abstract><trans-abstract xml:lang="en"><p>This review is devoted to the problem of drug-induced hypertension (H). It summarizes the literature data on drugs and substances that can increase blood pressure, discusses the mechanisms of their hypertensive action. Many classes of drugs such as steroids, nonsteroidal anti-inflammatory drugs, sympathomimetics, immunosuppressants, oral contraceptives, antidepressants, erythropoietin, etc. can cause episodic or persistent increase in blood pressure, cause uncontrolled hypertension, reduce the effectiveness of antihypertensive drugs. The development of drug-induced hypertension is realized through a number of pathophysiological mechanisms: sodium retention with subsequent increase in the volume of circulating blood, activation of the sympathetic nervous system, direct effect on the smooth muscles of arterioles, there are other, not fully studied mechanisms. Drug-induced H may also be the result of pharmacokinetic or pharmacodynamic drug interactions. To suspect the presence of drug-induced hypertension, in the first place, should be in persons with newly diagnosed hypertension, as well as in patients who previously had a well-controlled hypertension (stable target blood pressure - BP levels) when they have episodes of unexplained increase in BP without a clear relationship with physical or psycho-emotional stress. It is very important to have a properly collected history with a focus on a thorough assessment of the medicines taken by the patient, especially newly prescribed, as well as those purchased at the pharmacy independently, including over-the-counter, this will avoid unnecessary and/or expensive studies and unnecessary prescriptions of additional antihypertensive drugs. The article presents these measures for the prevention and correction of drug-induced H. The appointment of new drugs by a doctor to patients receiving antihypertensive therapy should necessarily take into account their impact on the risk of drug-induced hypertension. Prescribing drugs that cause an increase in BP levels should either be avoided or, if alternative treatment regimens are not possible, strict control of the patient's BP level (including the method of home monitoring of BP) and, if necessary, the correction of antihypertensive therapy. When canceling a drug that causes drug-induced hypertension, BP returns to its original level, which is proof of the iatrogenic cause of hypertension.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>лекарственно-индуцированная артериальная гипертония</kwd><kwd>вторичная артериальная гипертония</kwd><kwd>лекарственные средства</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>drug-induced hypertension</kwd><kwd>secondary arterial hypertension</kwd><kwd>drugs</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Diaconu C.C, Dediu G.N, Lancu M.A. Drug-induced arterial hypertension - a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1-7. DOI: 10.1080/00015385.2017.1421445</mixed-citation><mixed-citation xml:lang="en">Diaconu C.C, Dediu G.N, Lancu M.A. Drug-induced arterial hypertension - a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1-7. DOI: 10.1080/00015385.2017.1421445</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gyamlani G, Geraci S.A. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692-9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8</mixed-citation><mixed-citation xml:lang="en">Gyamlani G, Geraci S.A. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692-9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Page B, Amoura Z, Grunfeld J.P. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60-5.</mixed-citation><mixed-citation xml:lang="en">Page B, Amoura Z, Grunfeld J.P. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60-5.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan N.M. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams &amp; Wilkins, 1994; pp 343-65.</mixed-citation><mixed-citation xml:lang="en">Kaplan N.M. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams &amp; Wilkins, 1994; pp 343-65.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Whitworth J.A. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213-24.</mixed-citation><mixed-citation xml:lang="en">Whitworth J.A. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213-24.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Whitworth J.A, Brown M.A, Kelly J.J, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76-80.</mixed-citation><mixed-citation xml:lang="en">Whitworth J.A, Brown M.A, Kelly J.J, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76-80.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567-74.</mixed-citation><mixed-citation xml:lang="en">Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567-74.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Клиническая фармакология и фармакотерапия: учеб. для студентов медицинских вузов. Под ред. В.Г.Кукеса, А.К.Стародубцева. М.: ГЭОТАР-Медиа, 2012.</mixed-citation><mixed-citation xml:lang="en">Клиническая фармакология и фармакотерапия: учеб. для студентов медицинских вузов. Под ред. В.Г.Кукеса, А.К.Стародубцева. М.: ГЭОТАР-Медиа, 2012.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Brem A.S. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1-10.</mixed-citation><mixed-citation xml:lang="en">Brem A.S. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1-10.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ulick S, Levine L.S, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757-64. DOI: 10.1210/jcem-49-5-757</mixed-citation><mixed-citation xml:lang="en">Ulick S, Levine L.S, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757-64. DOI: 10.1210/jcem-49-5-757</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637-38.</mixed-citation><mixed-citation xml:lang="en">Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637-38.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Weir R.J. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212-5. DOI: 10.1177/003693308202700303</mixed-citation><mixed-citation xml:lang="en">Weir R.J. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212-5. DOI: 10.1177/003693308202700303</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.</mixed-citation><mixed-citation xml:lang="en">Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khaw K, Peart W.S. Blood pressure and contraceptive use. Br Med J 1982; 285: 402-7.</mixed-citation><mixed-citation xml:lang="en">Khaw K, Peart W.S. Blood pressure and contraceptive use. Br Med J 1982; 285: 402-7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Spellacy W.N, Birk S.A. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912-19.</mixed-citation><mixed-citation xml:lang="en">Spellacy W.N, Birk S.A. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912-19.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mandel F.P, Geola F.L, Lu J.K et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.</mixed-citation><mixed-citation xml:lang="en">Mandel F.P, Geola F.L, Lu J.K et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37-42.</mixed-citation><mixed-citation xml:lang="en">Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37-42.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Шмелева Е.В., Зиганшина Л.Е., Салихов И.Г. Побочные эффекты гормональных контрацептивов. Казанский мед. журн. 2006; 5: 366-9.</mixed-citation><mixed-citation xml:lang="en">Шмелева Е.В., Зиганшина Л.Е., Салихов И.Г. Побочные эффекты гормональных контрацептивов. Казанский мед. журн. 2006; 5: 366-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bretza J.A, Novey H.S, Vaziri N.D, Warner A.S. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379-80.</mixed-citation><mixed-citation xml:lang="en">Bretza J.A, Novey H.S, Vaziri N.D, Warner A.S. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379-80.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49-54.</mixed-citation><mixed-citation xml:lang="en">Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49-54.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38.</mixed-citation><mixed-citation xml:lang="en">Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Nisenbaum M.G, Melo N.R, Giribela C.R et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62-6. DOI: 10.1016/j.ejogrb.2014.01.006</mixed-citation><mixed-citation xml:lang="en">Nisenbaum M.G, Melo N.R, Giribela C.R et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62-6. DOI: 10.1016/j.ejogrb.2014.01.006</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Preston R.A, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816-22.</mixed-citation><mixed-citation xml:lang="en">Preston R.A, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816-22.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Preston R.A, White W.B, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797-804. DOI: 10.1016/j.amjhyper.2004.12.003</mixed-citation><mixed-citation xml:lang="en">Preston R.A, White W.B, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797-804. DOI: 10.1016/j.amjhyper.2004.12.003</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">White W.B, Pitt B, Preston R.A, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979-1980. DOI: 10.1161/CIRCULATIONAHA.104.501502</mixed-citation><mixed-citation xml:lang="en">White W.B, Pitt B, Preston R.A, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979-1980. DOI: 10.1161/CIRCULATIONAHA.104.501502</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">de Morais T.L, Giribela C, Nisenbaum M.G et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113-7. DOI: 10.1016/j.ejogrb.2014.09.006</mixed-citation><mixed-citation xml:lang="en">de Morais T.L, Giribela C, Nisenbaum M.G et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113-7. DOI: 10.1016/j.ejogrb.2014.09.006</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология: учебник для студентов медицинских вузов. М.: МЕДпресс-информ, 2004; с. 391-2.</mixed-citation><mixed-citation xml:lang="en">Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология: учебник для студентов медицинских вузов. М.: МЕДпресс-информ, 2004; с. 391-2.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Кулаков В.И., Кулаков В.И., Сметник В.П. Руководство по климактерию. М.: Медицинское информационное агентство, 2001; с. 404-95.</mixed-citation><mixed-citation xml:lang="en">Кулаков В.И., Кулаков В.И., Сметник В.П. Руководство по климактерию. М.: Медицинское информационное агентство, 2001; с. 404-95.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Барт Б.Я., Бороненков Г.М., Беневская В.Ф. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Рос. кардиол. журн. 2001; 5: 69-70. [Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69-70 (in Russian).]</mixed-citation><mixed-citation xml:lang="en">Барт Б.Я., Бороненков Г.М., Беневская В.Ф. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Рос. кардиол. журн. 2001; 5: 69-70. [Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69-70 (in Russian).]</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Курбанова З.К. Влияние низкодозированных комбинированных оральных контрацептивов на эндотелий сосудов. Архив акушерства и гинекологии им. В.Ф.Снегирева. 2015; 4: 46-7.</mixed-citation><mixed-citation xml:lang="en">Курбанова З.К. Влияние низкодозированных комбинированных оральных контрацептивов на эндотелий сосудов. Архив акушерства и гинекологии им. В.Ф.Снегирева. 2015; 4: 46-7.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771-81. DOI: 10.1016/S0140-6736(06)69666-9</mixed-citation><mixed-citation xml:lang="en">Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771-81. DOI: 10.1016/S0140-6736(06)69666-9</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013; 2.</mixed-citation><mixed-citation xml:lang="en">Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013; 2.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929-34.</mixed-citation><mixed-citation xml:lang="en">White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929-34.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161-8. DOI: 10.1001/archinte.165.2.161</mixed-citation><mixed-citation xml:lang="en">Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161-8. DOI: 10.1001/archinte.165.2.161</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236-9. DOI: 10.4061/2011/236239</mixed-citation><mixed-citation xml:lang="en">Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236-9. DOI: 10.4061/2011/236239</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Weber M.A. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004</mixed-citation><mixed-citation xml:lang="en">Weber M.A. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Johson A.G, Nguyen T.V, Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.</mixed-citation><mixed-citation xml:lang="en">Johson A.G, Nguyen T.V, Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Коцюбинская О.Б., Конев О.В., Дроздов В.Н. Влияние нестероидных противовоспалительных препаратов и трамала на уровень артериального давления при лечении остеоартроза у больных с артериальной гипертонией. Научно-практическая ревматология. 2004; 1: 28-33. DOI: 10.14412/1995-4484-2004-1</mixed-citation><mixed-citation xml:lang="en">Лазебник Л.Б., Коцюбинская О.Б., Конев О.В., Дроздов В.Н. Влияние нестероидных противовоспалительных препаратов и трамала на уровень артериального давления при лечении остеоартроза у больных с артериальной гипертонией. Научно-практическая ревматология. 2004; 1: 28-33. DOI: 10.14412/1995-4484-2004-1</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225-36. DOI: 10.1002/pds.2227</mixed-citation><mixed-citation xml:lang="en">Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225-36. DOI: 10.1002/pds.2227</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Fanelli A, Ghisi D, Aprile P.L, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173-82. DOI: 10.1177/2042098617690485</mixed-citation><mixed-citation xml:lang="en">Fanelli A, Ghisi D, Aprile P.L, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173-82. DOI: 10.1177/2042098617690485</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634-42. DOI: 10.1161/CIRCULATIONAHA.106.181424</mixed-citation><mixed-citation xml:lang="en">Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634-42. DOI: 10.1161/CIRCULATIONAHA.106.181424</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Houston M.C. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.</mixed-citation><mixed-citation xml:lang="en">Houston M.C. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Wong D.G, Spence J.D, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997-1001.</mixed-citation><mixed-citation xml:lang="en">Wong D.G, Spence J.D, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997-1001.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">White W.B, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.</mixed-citation><mixed-citation xml:lang="en">White W.B, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167-79. DOI: 10.1517/14740338.2014.846324</mixed-citation><mixed-citation xml:lang="en">Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167-79. DOI: 10.1517/14740338.2014.846324</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Houston M.C, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049-54.</mixed-citation><mixed-citation xml:lang="en">Houston M.C, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049-54.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Moore R.A, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73</mixed-citation><mixed-citation xml:lang="en">Moore R.A, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Furey S.A, Vargas R, McMahon F.G. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143-8.</mixed-citation><mixed-citation xml:lang="en">Furey S.A, Vargas R, McMahon F.G. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143-8.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59-66. doi.org/10.15829/1560-4071-2015-1-59-66.</mixed-citation><mixed-citation xml:lang="en">Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59-66. doi.org/10.15829/1560-4071-2015-1-59-66.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209-19. doi: 10.1097/01.SMJ.0000093569.26036.27</mixed-citation><mixed-citation xml:lang="en">Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209-19. doi: 10.1097/01.SMJ.0000093569.26036.27</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Combe B, Landewe R, Daien C.I. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948-59. DOI: 10.1136/annrheumdis-2016-210602</mixed-citation><mixed-citation xml:lang="en">Combe B, Landewe R, Daien C.I. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948-59. DOI: 10.1136/annrheumdis-2016-210602</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Hochberg M.C, Altman R.D, April K.T et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465-74.</mixed-citation><mixed-citation xml:lang="en">Hochberg M.C, Altman R.D, April K.T et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465-74.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Amsterdam J.D, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9-14.</mixed-citation><mixed-citation xml:lang="en">Amsterdam J.D, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9-14.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufmann J.S. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.</mixed-citation><mixed-citation xml:lang="en">Kaufmann J.S. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Loule A.K, Louie E.K, Lannon R.A. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306-9.</mixed-citation><mixed-citation xml:lang="en">Loule A.K, Louie E.K, Lannon R.A. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306-9.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502-8.</mixed-citation><mixed-citation xml:lang="en">Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502-8.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125-6.</mixed-citation><mixed-citation xml:lang="en">Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125-6.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118</mixed-citation><mixed-citation xml:lang="en">Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187-192.</mixed-citation><mixed-citation xml:lang="en">Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187-192.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Cain J.W. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910-2. DOI: 10.1176/ajp.143.7.910</mixed-citation><mixed-citation xml:lang="en">Cain J.W. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910-2. DOI: 10.1176/ajp.143.7.910</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Scott D.L, Smolen J.D, Kalden J.R et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913-23.</mixed-citation><mixed-citation xml:lang="en">Scott D.L, Smolen J.D, Kalden J.R et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913-23.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Akpunonu B.E, Mulrow P.J, Hoffman E.A. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689-702.</mixed-citation><mixed-citation xml:lang="en">Akpunonu B.E, Mulrow P.J, Hoffman E.A. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689-702.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L.X, Rustgi A.K. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060-4.</mixed-citation><mixed-citation xml:lang="en">Liu L.X, Rustgi A.K. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060-4.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Robert N, Wong G.W, Wright J.M. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858</mixed-citation><mixed-citation xml:lang="en">Robert N, Wong G.W, Wright J.M. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Cush J.J, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176-86.</mixed-citation><mixed-citation xml:lang="en">Cush J.J, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176-86.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Artz M.A, Boots J.M, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937-45. DOI: 10.1111/j.1600-6143.2004.00427.x</mixed-citation><mixed-citation xml:lang="en">Artz M.A, Boots J.M, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937-45. DOI: 10.1111/j.1600-6143.2004.00427.x</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460-8. DOI: 10.1038/ajh.2010.25</mixed-citation><mixed-citation xml:lang="en">Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460-8. DOI: 10.1038/ajh.2010.25</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Wu S, Chen J.J, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117-23. DOI: 10.1016/S1470-2045(08)70003-2</mixed-citation><mixed-citation xml:lang="en">Wu S, Chen J.J, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117-23. DOI: 10.1016/S1470-2045(08)70003-2</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Rini B.I, Schiller J.H, Fruehauf J.P et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841-9. DOI: 10.1158/1078-0432.CCR-10-2806</mixed-citation><mixed-citation xml:lang="en">Rini B.I, Schiller J.H, Fruehauf J.P et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841-9. DOI: 10.1158/1078-0432.CCR-10-2806</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Laragh J.H. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353-355.</mixed-citation><mixed-citation xml:lang="en">Laragh J.H. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353-355.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6</mixed-citation><mixed-citation xml:lang="en">Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.</mixed-citation><mixed-citation xml:lang="en">Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419-21.</mixed-citation><mixed-citation xml:lang="en">Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419-21.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Amaranath L, Zanettin G.G, Bravo E.L et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127-30.</mixed-citation><mixed-citation xml:lang="en">Amaranath L, Zanettin G.G, Bravo E.L et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127-30.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Joyce D.A, Gubbay S.S. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260-1.</mixed-citation><mixed-citation xml:lang="en">Joyce D.A, Gubbay S.S. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260-1.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor G.J. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821-2.</mixed-citation><mixed-citation xml:lang="en">Taylor G.J. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821-2.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Bakht F.R, Kirshon B, Baker T, Cotton D.B. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065-6.</mixed-citation><mixed-citation xml:lang="en">Bakht F.R, Kirshon B, Baker T, Cotton D.B. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065-6.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Watson D.L, Bhatia R., Norman G.S et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573-6.</mixed-citation><mixed-citation xml:lang="en">Watson D.L, Bhatia R., Norman G.S et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573-6.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Gorun G.S, Dermengiu D, Curca G.C et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271-9. DOI: 10.4323/rjlm.2010.271</mixed-citation><mixed-citation xml:lang="en">Gorun G.S, Dermengiu D, Curca G.C et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271-9. DOI: 10.4323/rjlm.2010.271</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Izzo A.A, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1-14. DOI: 10.1016/j.ijcard.2003.06.039</mixed-citation><mixed-citation xml:lang="en">Izzo A.A, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1-14. DOI: 10.1016/j.ijcard.2003.06.039</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Abhyankar L.N, Jones M.R, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494-500. DOI: 10.1289/ehp.1103988</mixed-citation><mixed-citation xml:lang="en">Abhyankar L.N, Jones M.R, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494-500. DOI: 10.1289/ehp.1103988</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125-8.</mixed-citation><mixed-citation xml:lang="en">Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125-8.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Saadeh A.M, Farsakh N.A, al-Ali M.K. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461-4.</mixed-citation><mixed-citation xml:lang="en">Saadeh A.M, Farsakh N.A, al-Ali M.K. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461-4.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159-64.</mixed-citation><mixed-citation xml:lang="en">World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159-64.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E, Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14-22. DOI: 10.1016/j.amjmed.2011.05.02</mixed-citation><mixed-citation xml:lang="en">Grossman E, Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14-22. DOI: 10.1016/j.amjmed.2011.05.02</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Lancu M.A, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a</mixed-citation><mixed-citation xml:lang="en">Lancu M.A, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
